Síndrome de Guillain-Barré en un paciente en tratamiento con bortezomib

María Mar Herráez-Albendea; Almudena Amorós-Paredes; Marta Arteta-Jiménez

doi:10.7399/fh.11340

Síndrome de Guillain-Barré en un paciente en tratamiento con bortezomib

María Mar Herráez-Albendea, Almudena Amorós-Paredes, Marta Arteta-Jiménez

Resumen

Texto completo:

PDF (English) PDF

Referencias

Xu YL, Zhao WH, Tang ZY, Li ZQ, Long Y, Cheng P, et al. Guillain-Barre syndrome in a patient with multiple myeloma after bortezomib therapy: A case report. World J Clin Cases. 2019;7(18):2905-9. DOI: 10.12998/wjcc.v7.i18.2905

Dai X, Sun X, Ni H, Zhu X. Guillain Barre syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report. Onco Lett. 2015;10(5):3064-6. DOI: 10.3892/ol.2015.3634

European Medicines Agency. Ficha técnica de bortezomib (Velcade®) [internet] [accessed 11/25/2019]. Available at: www.ema.europa.eu/en/documents/product-information/velcade- epar-product-information_es.pdf

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple Myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv52-61. DOI: 10.1093/annonc/mdx096

Fujimura H. The Guillain-Barre syndrome. Handb Clin Neurol. 2013;115:383-402. DOI: 10.1016/B978-0-444-52902-2.00021-7

Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med. 2012;366(24):2294-304. DOI: 10.1056/NEJMra1114525

Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113-20. DOI: 10.1200/JCO.2005.04.7779

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. DOI: 1038/clpt.1981.154

DOI: http://dx.doi.org/10.7399%2Ffh.11340